AU641434B2 - Assays and reagents for amyloid deposition - Google Patents

Assays and reagents for amyloid deposition

Info

Publication number
AU641434B2
AU641434B2 AU64311/90A AU6431190A AU641434B2 AU 641434 B2 AU641434 B2 AU 641434B2 AU 64311/90 A AU64311/90 A AU 64311/90A AU 6431190 A AU6431190 A AU 6431190A AU 641434 B2 AU641434 B2 AU 641434B2
Authority
AU
Australia
Prior art keywords
amyloid
preamyloid
val
protein
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU64311/90A
Other languages
English (en)
Other versions
AU6431190A (en
Inventor
Barbara Cordell
David Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
California Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Biotechnology Inc filed Critical California Biotechnology Inc
Publication of AU6431190A publication Critical patent/AU6431190A/en
Application granted granted Critical
Publication of AU641434B2 publication Critical patent/AU641434B2/en
Assigned to SCIOS NOVA INC. reassignment SCIOS NOVA INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CALIFORNIA BIOTECHNOLOGY, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU64311/90A 1989-09-18 1990-09-12 Assays and reagents for amyloid deposition Expired AU641434B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40876789A 1989-09-18 1989-09-18
US408767 1989-09-18

Publications (2)

Publication Number Publication Date
AU6431190A AU6431190A (en) 1991-04-18
AU641434B2 true AU641434B2 (en) 1993-09-23

Family

ID=23617679

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64311/90A Expired AU641434B2 (en) 1989-09-18 1990-09-12 Assays and reagents for amyloid deposition

Country Status (5)

Country Link
EP (1) EP0493470A4 (fr)
JP (1) JPH05502368A (fr)
AU (1) AU641434B2 (fr)
CA (1) CA2065404C (fr)
WO (1) WO1991004339A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3249793A (en) * 1991-12-24 1993-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for modulating beta -amyloid
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US7045290B2 (en) * 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
EP1793001B1 (fr) * 2001-02-15 2011-11-09 The University of Chicago Cribles à base de levure pour agents affectant le repliement de protéines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304013A2 (fr) * 1987-08-15 1989-02-22 Asahi Kasei Kogyo Kabushiki Kaisha Protéine précurseur de l'amyloide sénile et un anticorps spécifique
WO1989006693A1 (fr) * 1988-01-13 1989-07-27 The Mclean Hospital Corporation Sequences genetiques codant pour l'amyloide cerebrale d'alzheimer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403557A1 (fr) * 1977-09-19 1979-04-13 Beljanski Mirko Procede et reactifs de detection des substances cancerigenes et des substances anticancereuses
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
ES2120401T3 (es) * 1986-11-17 1998-11-01 Scios Inc Proteina recombinante amiloide relacionados con la enfermedad de alzheimer.
US4912206A (en) * 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
CA1339014C (fr) * 1987-10-08 1997-03-25 Ronald E. Majocha Anticorps pour peptide a4-amyloide
WO1989007657A1 (fr) * 1988-02-10 1989-08-24 The Children's Medical Center Corporation Precurseurs de proteines amyloides, sondes genetiques, anticorps, et modes d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304013A2 (fr) * 1987-08-15 1989-02-22 Asahi Kasei Kogyo Kabushiki Kaisha Protéine précurseur de l'amyloide sénile et un anticorps spécifique
WO1989006693A1 (fr) * 1988-01-13 1989-07-27 The Mclean Hospital Corporation Sequences genetiques codant pour l'amyloide cerebrale d'alzheimer

Also Published As

Publication number Publication date
EP0493470A4 (en) 1992-11-25
AU6431190A (en) 1991-04-18
EP0493470A1 (fr) 1992-07-08
CA2065404A1 (fr) 1991-03-19
WO1991004339A1 (fr) 1991-04-04
CA2065404C (fr) 2002-12-24
JPH05502368A (ja) 1993-04-28

Similar Documents

Publication Publication Date Title
US5221607A (en) Assays and reagents for amyloid deposition
Otvos Jr et al. Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404
US6610493B1 (en) Screening compounds for the ability to alter the production of amyloid-β peptide
EP0736106B2 (fr) Procede de detection d'inhibiteurs de la production de peptides beta-amyloides
CA2205359C (fr) Methode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x->=41) et de la proteine tau
US5593846A (en) Methods for the detection of soluble β-amyloid peptide
CA2118243C (fr) Methodes et compositions pour surveiller le traitement par les cellules de la proteine precurseur .beta.-amyloide
US5837672A (en) Methods and compositions for the detection of soluble β-amyloid peptide
US5605811A (en) Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US7479372B2 (en) Beta-secretase substrates and uses thereof
US5733734A (en) Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
WO1997048983A9 (fr) CRIBLAGE DE COMPOSES CAPABLES DE MODIFIER LA PRODUCTION DE PEPTIDE AMYLOIDE-β (x-≥41)
AU641434B2 (en) Assays and reagents for amyloid deposition